Back to catalog
GrowthModerate evidence

Ipamorelin

Selective growth hormone secretagogue with a cleaner side-effect profile than earlier GHRPs in comparative research.

Half-life
~2 hours
Administration
Subcutaneous injection
Primary uses
GH pulse support · Recovery stacks · Sleep-associated protocols

Mechanism

Ghrelin-receptor (GHS-R1a) agonist that stimulates GH release with relatively minimal cortisol and prolactin impact.

  • GH pulse support
  • Recovery stacks
  • Sleep-associated protocols

Dosing ranges

Educational ranges only — not medical advice. Confirm protocols with a qualified clinician.

Use caseTypical rangeFrequencyNotes
Research GH support100–300 mcg1–3× dailyCommonly timed around sleep or training in non-clinical protocols

Clinical evidence

Moderate evidence
Eur J Endocrinol · 1998

Ipamorelin, a novel selective growth hormone secretagogue

Potent GH release with reduced ACTH/cortisol stimulation vs older GHRPs.

Cautions

  • Hunger effects are usually milder than GHRP-6 but still possible
  • Quality varies in research markets
  • Should not be used to self-treat endocrine disease

Provider comparison

Affiliate-style comparison cards for clinics, telehealth, and research suppliers. Verify licensing and product quality before purchasing.

Fountain Health
telehealth
4.7
From $249/mo

Licensed clinician consult + ongoing titration support

Compare offer
PeakRx Clinic
clinic
4.5
From $189/mo

In-person labs available in select metros

Compare offer
Research Supply Co.
research
4.1
Vial pricing

Research-only sourcing — not for human consumption labeling

View listing
Growth
Moderate evidence

CJC-1295

Growth hormone releasing hormone analog designed to elevate GH and IGF-1 with extended activity versus native GHRH.

GH axis supportView research →
Growth
Moderate evidence

GHRP-6

Growth hormone releasing peptide that also strongly increases appetite — useful or limiting depending on the goal.

GH release researchView research →